CC-90003
Drug
Celgene Corporation
Total Payments
$132,953
Transactions
7
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $132,953 | 7 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $132,953 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-90003-ST-001 | Celgene Corporation | $132,953 | 3 |
Ad
Manufacturing Companies
- Celgene Corporation $132,953
Product Information
- Type Drug
- Total Payments $132,953
- Total Doctors 3
- Transactions 7
About CC-90003
CC-90003 is a drug associated with $132,953 in payments to 3 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2017. In 2017, $132,953 was paid across 7 transactions to 3 doctors.
The most common payment nature for CC-90003 is "Unspecified" ($132,953, 100.0% of total).
CC-90003 is associated with 1 research study, including "CC-90003-ST-001" ($132,953).